66 related articles for article (PubMed ID: 11092568)
1. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
Sadler BM; Gillotin C; Lou Y; Eron JJ; Lang W; Haubrich R; Stein DS
Antimicrob Agents Chemother; 2001 Dec; 45(12):3663-8. PubMed ID: 11709366
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus.
Sudhakaran S; Rayner CR; Li J; Kong DC; Gude NM; Nation RL
Br J Clin Pharmacol; 2008 May; 65(5):667-73. PubMed ID: 18093255
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects.
DiCenzo R; Forrest A; Fischl MA; Collier A; Feinberg J; Ribaudo H; DiFrancecso R; Morse GD;
Antimicrob Agents Chemother; 2004 Mar; 48(3):918-23. PubMed ID: 14982784
[TBL] [Abstract][Full Text] [Related]
4. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease.
Sham HL; Kempf DJ; Molla A; Marsh KC; Kumar GN; Chen CM; Kati W; Stewart K; Lal R; Hsu A; Betebenner D; Korneyeva M; Vasavanonda S; McDonald E; Saldivar A; Wideburg N; Chen X; Niu P; Park C; Jayanti V; Grabowski B; Granneman GR; Sun E; Japour AJ; Leonard JM; Plattner JJ; Norbeck DW
Antimicrob Agents Chemother; 1998 Dec; 42(12):3218-24. PubMed ID: 9835517
[TBL] [Abstract][Full Text] [Related]
5. Interaction between saquinavir soft-gel and rifabutin in patients infected with HIV.
Moyle GJ; Buss NE; Goggin T; Snell P; Higgs C; Hawkins DA
Br J Clin Pharmacol; 2002 Aug; 54(2):178-82. PubMed ID: 12207638
[TBL] [Abstract][Full Text] [Related]
6. Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
Payen S; Faye A; Compagnucci A; Giaquinto C; Gibbs D; Gomeni R; Bressolle F; Jacqz-Aigrain E
Antimicrob Agents Chemother; 2005 Feb; 49(2):525-35. PubMed ID: 15673728
[TBL] [Abstract][Full Text] [Related]
7. A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial.
Jackson KA; Rosenbaum SE; Kerr BM; Pithavala YK; Yuen G; Dudley MN
Antimicrob Agents Chemother; 2000 Jul; 44(7):1832-7. PubMed ID: 10858338
[TBL] [Abstract][Full Text] [Related]
8. Oral contraception does not alter single dose saquinavir pharmacokinetics in women.
Fröhlich M; Burhenne J; Martin-Facklam M; Weiss J; von Wolff M; Strowitzki T; Walter-Sack I; Haefeli WE
Br J Clin Pharmacol; 2004 Mar; 57(3):244-52. PubMed ID: 14998420
[TBL] [Abstract][Full Text] [Related]
9. Antiretroviral Drug Levels and Interactions Affect Lipid, Lipoprotein, and Glucose Metabolism in HIV-1 Seronegative Subjects: A Pharmacokinetic-Pharmacodynamic Analysis.
Rosenkranz SL; Yarasheski KE; Para MF; Reichman RC; Morse GD
Metab Syndr Relat Disord; 2007 Jun; 5(2):163-73. PubMed ID: 18007962
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of novel Saquinavir analogs for resistance mutation compatibility and potential as an HIV-Protease inhibitor drug.
Jayaswal A; Mishra A; Mishra H; Shah K
Bioinformation; 2014; 10(4):227-32. PubMed ID: 24966525
[TBL] [Abstract][Full Text] [Related]
11. Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir.
Xie L; Evangelidis T; Xie L; Bourne PE
PLoS Comput Biol; 2011 Apr; 7(4):e1002037. PubMed ID: 21552547
[TBL] [Abstract][Full Text] [Related]
12. Lead expansion and virtual screening of Indinavir derivate HIV-1 protease inhibitors using pharmacophoric - shape similarity scoring function.
Shityakov S; Dandekar T
Bioinformation; 2010 Jan; 4(7):295-9. PubMed ID: 20978602
[TBL] [Abstract][Full Text] [Related]
13. Repositioning HIV protease inhibitors as cancer therapeutics.
Bernstein WB; Dennis PA
Curr Opin HIV AIDS; 2008 Nov; 3(6):666-75. PubMed ID: 19373040
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology and pharmacokinetics of amprenavir.
Sadler BM; Stein DS
Ann Pharmacother; 2002 Jan; 36(1):102-18. PubMed ID: 11816239
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.
Zion O; Genin O; Kawada N; Yoshizato K; Roffe S; Nagler A; Iovanna JL; Halevy O; Pines M
Pancreas; 2009 May; 38(4):427-35. PubMed ID: 19188864
[TBL] [Abstract][Full Text] [Related]
16. Dietary fibre, nuts and cardiovascular diseases.
Salas-Salvadó J; Bulló M; Pérez-Heras A; Ros E
Br J Nutr; 2006 Nov; 96 Suppl 2():S46-51. PubMed ID: 17125533
[TBL] [Abstract][Full Text] [Related]
17. Dietary Intake and Coronary Heart Disease: A Variety of Nutrients and Phytochemicals Are Important.
Tucker KL
Curr Treat Options Cardiovasc Med; 2004 Aug; 6(4):291-302. PubMed ID: 15212724
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
